Nanox Imaging reports Q4 2025 results and strategic restructuring of Korean operations
NANO-X IMAGING (NASDAQ:NNOX), an innovative medical imaging technology company, today reported financial results for the fourth quarter ended December 31, 2025.
Todas as matérias desta categoria, das mais recentes às mais antigas.
NANO-X IMAGING (NASDAQ:NNOX), an innovative medical imaging technology company, today reported financial results for the fourth quarter ended December 31, 2025.
MainStreet Bancshares (NASDAQ:MNSB), the holding company for MainStreet Bank, today reported net income of $4.1 million, or $0.48 per diluted common share, for the quarter ended March 31, 2026.
YY Group Holding (NASDAQ:YYGH), a data-driven human resources and business process outsourcing provider, today reported its unaudited financial results for the fiscal year ended December 31, 2025.
QuidelOrtho (NASDAQ:QDEL), a global powerhouse in in vitro diagnostics, has announced the acquisition of LEX Diagnostics.
AstraZeneca (NASDAQ:AZN) today announced positive high-level results from its pivotal Phase III MIRANDA trial, evaluating tozorakimab as a maintenance treatment for patients with chronic obstructive pulmonary disease (COPD).
Clearmind Medicine (NASDAQ:CMND), a clinical-stage pharmaceutical company focused on developing novel psychedelic-derived therapies, announced today that its lead candidate, CMND-100, has successfully met the primary safety and tolerability endpoints in its Phase I/IIa clinical trial.
Capital City Bank Group (NASDAQ:CCBG) today reported financial results for the first quarter ended March 31, 2026, delivering a consistent performance characterized by disciplined expense management and improved capital metrics.
Biogen (NASDAQ:BIIB) announced today that it has entered into a definitive agreement to acquire the exclusive Greater China rights for felzartamab from TJ Biopharma.
Surf Air Mobility (NYSE:SRFM), a leading regional air mobility platform, today announced a major upward revision to its financial outlook for the 2026 fiscal year.
Genprex (NASDAQ:GNPX), a clinical-stage gene therapy company, announced today that its collaborators presented compelling preclinical data for its lead drug candidate, Reqorsa® (quaratusugene ozeplasmid), at the American Association for Cancer Research (AACR) Annual Meeting 2026.
Stanley Black & Decker (NYSE:SWK) announced today that recent adjustments to the Section 232 tariff regime—the federal trade policy governing aluminum and steel imports—are not expected to have a material impact on the company’s full-year 2026 financial guidance.
Honeywell (NASDAQ:HON) announced today that it has entered into a definitive agreement to sell its Productivity Solutions and Services (PSS) business to Brady Corporation (NYSE:BRC) for $1.4 billion in an all-cash transaction.
Tem um segundo para um cookie? 🍪Os cookies essenciais mantêm a Grafa funcionando bem. Alguns opcionais nos ajudam a ver o que está funcionando para melhorarmos. Você tem o controle — pode mudar de ideia quando quiser. Política de cookies · Política de privacidade